OTCMKTS:NGENF NervGen Pharma (NGENF) Stock Price, News & Analysis $2.46 -0.03 (-1.17%) As of 08/1/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesShort InterestBuy This Stock About NervGen Pharma Stock (OTCMKTS:NGENF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NervGen Pharma alerts:Sign Up Key Stats Today's Range$2.40▼$2.5050-Day Range$2.11▼$4.1052-Week Range$1.46▼$5.10Volume62,017 shsAverage Volume137,678 shsMarket Capitalization$151.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada. Read More Receive NGENF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NervGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NGENF Stock News HeadlinesNervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update - Seeking AlphaJuly 9, 2025 | seekingalpha.comNervGen Pharma Corp.: NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options UpdateJuly 7, 2025 | finanznachrichten.deWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.August 2 at 2:00 AM | InvestorPlace (Ad)NervGen Pharma Updates on Equity Program and Stock OptionsJuly 7, 2025 | tipranks.comNervGen Pharma (NGENF) Gets a Buy from Raymond JamesJune 13, 2025 | theglobeandmail.comNervGen Pharma-Aktie stürzt nach Ergebnissen klinischer Studie abJune 2, 2025 | de.investing.comNervGen Pharma stock tumbles following clinical trial resultsJune 2, 2025 | in.investing.comNervGen, Sprott Climb to 52-Week Highs on NewsMay 21, 2025 | baystreet.caSee More Headlines NGENF Stock Analysis - Frequently Asked Questions How have NGENF shares performed this year? NervGen Pharma's stock was trading at $2.18 on January 1st, 2025. Since then, NGENF stock has increased by 12.8% and is now trading at $2.46. How do I buy shares of NervGen Pharma? Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/02/2025Next Earnings (Estimated)8/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:NGENF CIKN/A WebN/A Phone(778) 731-1711FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.07 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-56.59% Debt Debt-to-Equity Ratio0.04 Current Ratio11.21 Quick Ratio11.21 Sales & Book Value Annual Sales$150 thousand Price / Sales1,013.03 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares61,770,000Free FloatN/AMarket Cap$151.95 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:NGENF) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NervGen Pharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share NervGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
